Clinical trials: Lung Neoplasm Malignant
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase 2, open-label, multicenter study to assess the efficacy and safety of second/third-line treatment with nab-paclitaxel in combination with the epigenetic modifying therapy of CC-486 or immunotherapy of durvalumab…
- Trial name
- abound2L+ (NCT02250326)
- Testing
- nab-paclitaxel IV, CC-486, Duravalumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 240 people
- Sponsor
- Celgene
Lung Cancer
Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage
The goal of this multicenter observational study is to evaluate the lung cancer diagnostic value of epigenetic imprinting detection in bronchoalveolar lavage.
- Trial name
- NCT05707585
- Testing
- Quantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH)
- Where
- 3 sites in China
- Volunteers
- 2,064 people
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
Lung Cancer
The Role of Narrow Band Imaging Videobronchoscopy in Lung Cancer
Narrow band imaging (NBI) videobronchoscopy is an optical technique in which filtered light enhances superficial neoplasm based on their neoangiogenic pattern.
- Trial name
- NBI (NCT01178190)
- Where
- South Korea
- Volunteers
- 101 people
- Sponsor
- Asan Medical Center
Squamous Cell Lung Cancer
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor.
- Trial name
- NCT05607108
- Testing
- ZEN003694
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC
The purpose of this study is to assess the maximum tolerated dose of low-dose radiation in combination with Docetaxel in recurrent or metastatic non-small cell lung cancer for second-line therapy.
- Trial name
- NCT00378404
- Testing
- Docetaxel, Radiation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Susanne Arnold
Mesothelioma, Malignant
Malignant Mesothelioma - Can we Improve Quality of Life
Patients with malignant pleural mesothelioma (MPM) frequently have significant physical symptoms, with up to 92% of patients complaining of three or more symptoms at presentation.
- Trial name
- RESPECT-Meso (NCT03068117)
- Testing
- Regular Early Specialist Symptom Control Treatment (RESSCT)
- Where
- 19 sites in Australia, United Kingdom
- Volunteers
- 319 people
- Sponsor
- Portsmouth Hospitals NHS Trust
Advanced Cancer, Ovarian Cancer
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
- Conditions
- Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT03667716
- Testing
- COM701, COM701 with Opdivo (Nivolumab).
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Compugen Ltd
Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back…
- Conditions
- Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT03213652
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 126 sites in United States, Australia and 2 more
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative
Intratumoral N17350 in Advanced Solid Tumors
The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies.
- Conditions
- Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma
- Trial name
- OP-NEU-101 (NCT07339176)
- Testing
- N17350
- Where
- 9 sites in United States, Australia
- Volunteers
- 275 people
- Sponsor
- Onchilles Pharma Inc
Carcinoma, Non-Small-Cell Lung, Urinary Bladder Neoplasms
Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
Carboplatin kills cancer cells mainly through induction of DNA damage (drug-DNA adducts). The goal of this clinical trial is to determine if chemoresistance to carboplatin can be identified by measuring carboplatin-induced DNA…
- Trial name
- NCT01261299
- Testing
- Carbon-14-labeled carboplatin
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of California, Davis
Malignant Pleural Mesothelioma
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Study of galinpepimut-S, a Wilms Tumor-1 (WT1) vaccine, to see if it delays or prevents the mesothelioma from growing back after surgery. WT1 is a protein in cancer cells that regulates gene expression and causes cell growth.
- Trial name
- NCT01265433
- Testing
- Galinpepimut-S + Montanide + GM-CSF, Montanide + GM-CSF
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sellas Life Sciences Group
Lung Cancer, Metastatic Cancer
Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer
RATIONALE: Studying samples of pleural fluid in the laboratory from patients with lung cancer may help doctors identify early lung cancer cells. It may also help the study of lung cancer in the future.
- Trial name
- NCT00897143
- Testing
- microarray analysis, mutation analysis, flow cytometry
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Lung Neuroendocrine Neoplasm, GEP Neuroendocrine Tumor
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
The aim of CABOTEM study is to demonstrate the safety and activity of the Cabozantinib and Temozolomide combination in Lung and GEP-NENs patients, progressing after a first line therapy, including target therapies (everolimus…
- Trial name
- CABOTEM (NCT04893785)
- Testing
- Cabozantinib and Temozolomide
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute, Naples
Breast Neoplasms, Radiation Pneumonia
Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort
Prospective cohort research to study the state of oxygen metabolism, reserve capabilities of cardiovascular and respiratory systems in patients with breast cancer to create a program of prevention and rehabilitation of lung…
- Conditions
- Breast Neoplasms, Radiation Pneumonia, Radiation Pneumonitis, Radiation Induced Fibrosis
- Trial name
- RELIEF-COHORT (NCT06069115)
- Testing
- Radiation therapy protocol for Breast cancer, Spirography and assessment of pulmonary diffusion capacity, Cardiopulmonary stress test
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia
Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children
The aim of this study was to investigate the occurrences of respiratory symptoms risk factors and abnormalities in lung function in young children (3-6 years old) with hemato-oncologic diseases at presentation (before treatment)…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia, Solid Tumors,, Hodgkin's Disease
- Trial name
- NCT00552825
- Where
- Israel
- Volunteers
- 35 people
- Sponsor
- Sheba Medical Center
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical activity of etrumadenant (AB928) in combination…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
- Trial name
- ARC-4 (NCT03846310)
- Testing
- Etrumadenant, Zimberelimab, Carboplatin
- Where
- 22 sites in United States, Singapore and 2 more
- Volunteers
- 77 people
- Sponsor
- Arcus Biosciences, Inc.
Malignant Mesothelioma, Metastatic Cancer
Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia
RATIONALE: Studying levels of mesothelin and osteopontin in samples of blood from patients with mesothelioma or atypical mesothelial hyperplasia may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00899613
- Testing
- laboratory biomarker analysis, study of high risk factors
- Where
- France
- Volunteers
- 270 people
- Sponsor
- University Hospital, Caen
Malignant Mesothelioma
Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma
RATIONALE: Ganciclovir may ease some of the side effects of cancer treatment. Vaccines made from a person's modified malignant mesothelioma cells may make the cancer more sensitive to ganciclovir.
- Trial name
- NCT00006216
- Testing
- PA-1-STK ovarian carcinoma vaccine, ganciclovir
- Where
- United States
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Trial name
- DUET-3 (NCT03752398)
- Testing
- XmAb®23104, Yervoy® (ipilimumab)
- Where
- 18 sites in United States
- Volunteers
- 198 people
- Sponsor
- Xencor, Inc.
Malignant Pleural Mesothelioma
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Mesothelioma is an aggressive form of cancer. Treatments are available, but for many people, a cure isn't possible. This thesis is to assess the efficacy and safety of switch-maintenance Gemcitabine in Mesothelioma patients after…
- Trial name
- NCT05660616
- Testing
- Gemcitabine, supportive care
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Ain Shams University